Advertisement
UK markets close in 7 hours 31 minutes
  • FTSE 100

    8,125.01
    +46.15 (+0.57%)
     
  • FTSE 250

    19,748.50
    +146.52 (+0.75%)
     
  • AIM

    755.69
    +2.57 (+0.34%)
     
  • GBP/EUR

    1.1654
    -0.0003 (-0.02%)
     
  • GBP/USD

    1.2508
    -0.0003 (-0.03%)
     
  • Bitcoin GBP

    51,394.60
    +220.51 (+0.43%)
     
  • CMC Crypto 200

    1,387.87
    -8.67 (-0.62%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     
  • GOLD FUTURES

    2,357.60
    +15.10 (+0.64%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,666.03
    +381.49 (+2.21%)
     
  • DAX

    18,018.32
    +101.04 (+0.56%)
     
  • CAC 40

    8,039.68
    +23.03 (+0.29%)
     

Why Beam Therapeutics Climbed 64.5% in June

Why Beam Therapeutics Climbed 64.5% in June

Shares of Beam Therapeutics (NASDAQ: BEAM) jumped almost 65% last month according to S&P Global Market Intelligence. The move was in concert with other gene editing companies after Intellia Therapeutics and Regeneron announced results from a phase 1 study. The data indicated the pair had successfully used CRISPR-Cas9 to treat a rare liver disease.